benzyl alcohol - Profile

What are the generic drug sources for benzyl alcohol and what is the scope of freedom to operate?

Benzyl alcohol is the generic ingredient in one branded drug marketed by Shionogi Inc and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for benzyl alcohol

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for benzyl alcohol

Paragraph IV (Patent) Challenges for BENZYL ALCOHOL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ULESFIA	Lotion	benzyl alcohol	5%	022129	1	2016-04-11

US Patents and Regulatory Information for benzyl alcohol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Shionogi Inc	ULESFIA	benzyl alcohol	LOTION;TOPICAL	022129-001	Apr 9, 2009		DISCN	Yes	No

Expired US Patents for benzyl alcohol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Shionogi Inc	ULESFIA	benzyl alcohol	LOTION;TOPICAL	022129-001	Apr 9, 2009	5,858,383
Shionogi Inc	ULESFIA	benzyl alcohol	LOTION;TOPICAL	022129-001	Apr 9, 2009	6,139,859
Shionogi Inc	ULESFIA	benzyl alcohol	LOTION;TOPICAL	022129-001	Apr 9, 2009	7,294,342
Shionogi Inc	ULESFIA	benzyl alcohol	LOTION;TOPICAL	022129-001	Apr 9, 2009	6,793,931

Benzyl Alcohol: Market Fundamentals and Investment Outlook

Last updated: February 19, 2026

Benzyl alcohol (CAS No. 100-51-6) is a primary aromatic alcohol with broad applications across the pharmaceutical, cosmetic, and industrial sectors. Its utility as a solvent, preservative, and viscosity agent underpins a stable demand, though pricing and market growth are subject to raw material costs, regulatory shifts, and therapeutic area trends in pharmaceuticals. This analysis focuses on benzyl alcohol's role in the pharmaceutical industry, examining its market dynamics, competitive landscape, and potential investment considerations.

What is the Pharmaceutical Role of Benzyl Alcohol?

Benzyl alcohol serves multiple critical functions within pharmaceutical formulations. Its primary roles include:

• Preservative: Benzyl alcohol is a widely used bacteriostatic agent in injectable and topical pharmaceutical products. It prevents the growth of microorganisms, thereby maintaining product sterility and extending shelf life. Its efficacy is particularly notable against Gram-positive and Gram-negative bacteria. Common concentrations range from 0.5% to 2.0% in parenteral formulations.
• Solvent: Its lipophilic and hydrophilic properties make benzyl alcohol an effective solvent for a range of active pharmaceutical ingredients (APIs) and excipients that may have limited solubility in aqueous or non-aqueous bases. This facilitates the development of stable and bioavailable drug formulations.
• Viscosity Agent/Co-solvent: Benzyl alcohol can adjust the viscosity of liquid pharmaceutical formulations, aiding in consistent dosing and administration. It also functions as a co-solvent, improving the solubility and stability of other components.
• Anesthetic/Analgesic (Minor Role): At higher concentrations, benzyl alcohol exhibits mild local anesthetic properties. This is sometimes exploited in topical preparations for pain relief, though it is not its primary pharmaceutical application.

The U.S. Food and Drug Administration (FDA) permits benzyl alcohol in drug products as an inactive ingredient. The European Medicines Agency (EMA) also recognizes its use. Safety profiles are generally favorable at approved concentrations, though potential side effects like transient burning or stinging at the injection site, and rare allergic reactions, are documented.

What are the Key Market Drivers for Benzyl Alcohol in Pharmaceuticals?

Several factors drive demand for benzyl alcohol in the pharmaceutical sector:

• Growth in Injectable Drug Market: The expanding market for injectable biologics, vaccines, and generic injectable drugs is a primary driver. These formulations often require preservatives to maintain sterility, and benzyl alcohol is a cost-effective and well-established option. The global injectable drug market was valued at approximately USD 400 billion in 2023 and is projected to grow at a CAGR of 8.5% through 2030. [1]
• Demand for Preservative-Free Formulations (Counter-Driver): While demand for preservatives is strong, there is a growing trend towards "preservative-free" formulations, especially for multi-dose injectables and ophthalmic solutions, to mitigate potential toxicity concerns or patient sensitivities. This represents a competitive pressure.
• Generic Drug Production: The robust production of generic pharmaceuticals, particularly injectables, relies on established and cost-efficient excipients like benzyl alcohol. Generic drug manufacturing accounts for a significant portion of the pharmaceutical market.
• Emerging Markets: Increasing healthcare expenditure and the expansion of pharmaceutical manufacturing capabilities in emerging economies in Asia-Pacific and Latin America are driving demand for pharmaceutical excipients, including benzyl alcohol.
• Regulatory Acceptance: Benzyl alcohol's long history of safe and effective use, coupled with its widespread regulatory approval across major markets, solidifies its position as a preferred excipient.

What is the Supply Chain and Production Landscape?

The production of benzyl alcohol is primarily derived from the hydrolysis of benzyl chloride or the catalytic hydrogenation of benzaldehyde. Key raw materials include toluene and chlorine for benzyl chloride production, or benzaldehyde itself.

The global supply chain is characterized by:

• Major Producers: Leading chemical manufacturers globally produce benzyl alcohol. Key players include Lanxess AG, INEOS, Celanese Corporation, Saudi Basic Industries Corporation (SABIC), and Emerald Kalama Chemical.
• Geographic Concentration: Production is concentrated in regions with strong petrochemical infrastructure, such as North America, Europe, and Asia-Pacific. China has emerged as a significant producer and exporter.
• Raw Material Volatility: The price of benzyl alcohol is closely linked to the cost of its petrochemical precursors, particularly toluene. Fluctuations in crude oil prices and regional supply-demand dynamics for toluene can impact benzyl alcohol production costs and, consequently, its market price.
• Quality Standards: Pharmaceutical-grade benzyl alcohol must meet stringent purity requirements and pharmacopeial standards (e.g., USP, EP, JP). Manufacturers must adhere to Good Manufacturing Practices (GMP).
• Capacity Utilization: Global production capacity is generally sufficient to meet current demand, though regional supply disruptions or sudden demand spikes can lead to temporary price increases or shortages.

What are the Competitive Dynamics and Key Players?

The benzyl alcohol market, particularly for pharmaceutical grades, is competitive, with established chemical companies holding significant market share. Key competitive factors include:

• Product Quality and Purity: Meeting pharmacopeial standards and providing consistent high-purity product is paramount for pharmaceutical applications.
• Regulatory Compliance: Adherence to GMP and successful navigation of regulatory requirements in different regions are essential.
• Cost Competitiveness: Efficiency in production and access to cost-effective raw materials are critical for maintaining competitive pricing.
• Supply Chain Reliability: Ensuring consistent and timely delivery to pharmaceutical manufacturers is a key differentiator.
• Technical Support: Providing formulation support and technical expertise to pharmaceutical clients can foster stronger relationships.

Key Companies in Benzyl Alcohol Production (Pharmaceutical Grade):

• Lanxess AG: A major global producer with a broad portfolio of specialty chemicals, including benzyl alcohol, serving pharmaceutical and other industries.
• INEOS: A significant chemical manufacturer with production capabilities for benzyl alcohol.
• Celanese Corporation: A diversified chemical company with a presence in the benzyl alcohol market.
• Emerald Kalama Chemical (now part of LANXESS): Historically a prominent producer of benzyl alcohol and its derivatives.
• SABIC: A large petrochemical company with diversified chemical production.

Competitive Trends:

• Consolidation: The chemical industry has seen ongoing consolidation, with larger players acquiring smaller competitors to gain market share and diversify product portfolios.
• Focus on Specialty Grades: Increased emphasis on producing high-purity, pharmaceutical-grade benzyl alcohol with enhanced specifications to meet evolving regulatory and customer demands.
• Regional Expansion: Investment in production facilities in high-growth regions, particularly Asia, to serve local pharmaceutical markets more efficiently.

What is the Pricing and Revenue Outlook?

Benzyl alcohol pricing is influenced by raw material costs, production capacity, and demand from various end-use industries, with the pharmaceutical sector being a significant price influencer due to its quality requirements.

• Price Range: Pharmaceutical-grade benzyl alcohol typically ranges from USD 2.50 to USD 5.00 per kilogram, depending on volume, purity grade, and regional market dynamics. Industrial grades may be priced lower.
• Cost Drivers: Toluene prices are a principal determinant of benzyl alcohol manufacturing costs. For instance, if toluene prices increase by 10%, the cost of producing benzyl alcohol can rise by approximately 5-7%. [2]
• Market Size: The global benzyl alcohol market was estimated to be between USD 500 million and USD 700 million in 2023. [3]
• Projected Growth: The market is expected to grow at a Compound Annual Growth Rate (CAGR) of 3.5% to 5.0% over the next five to seven years, driven by demand from pharmaceuticals, personal care, and coatings. The pharmaceutical segment represents approximately 25-35% of the total market volume.
• Revenue Drivers: Revenue growth will be directly correlated with volume increases and price stability or modest increases, moderated by raw material cost fluctuations and the impact of competitive pricing.

What are the Regulatory and Safety Considerations?

Regulatory compliance is paramount for pharmaceutical applications of benzyl alcohol.

• Pharmacopeial Standards: Benzyl alcohol must comply with USP (United States Pharmacopeia), EP (European Pharmacopoeia), and JP (Japanese Pharmacopoeia) monographs. These define purity limits, assay requirements, and testing procedures. For example, the USP monograph specifies a minimum purity of 99.0% and limits for specific impurities like benzaldehyde and chlorobenzene. [4]
• GRAS Status: Benzyl alcohol is generally recognized as safe (GRAS) by the FDA for use in food, and its use in pharmaceuticals is well-established and regulated.
• Concentration Limits: Regulatory bodies and pharmacopeias often specify maximum allowable concentrations for benzyl alcohol in different types of drug products to ensure safety. For instance, in parenteral products, typical use levels are up to 2%, but specific indications might have different limits. [5]
• "Breathe-Easy" Concerns (Neonates): A critical safety consideration is the potential for "gasping syndrome" in premature neonates when benzyl alcohol is administered intravenously at high doses. This has led to strict recommendations against its use in neonatal intensive care units or very low birth weight infants. This has also spurred a market for preservative-free benzyl alcohol or alternative preservatives.
• Allergenicity: While rare, allergic reactions and hypersensitivity to benzyl alcohol can occur in certain individuals, leading to contact dermatitis or systemic reactions.
• REACH and Other Chemical Regulations: Manufacturers and importers must comply with chemical registration, evaluation, authorization, and restriction regulations like REACH in Europe and TSCA in the United States.

What are the Risks and Challenges?

Several risks and challenges can impact the investment landscape for benzyl alcohol:

• Raw Material Price Volatility: Fluctuations in toluene prices directly impact profit margins. A sustained rise in crude oil prices can significantly increase production costs.
• Intensifying Competition: The market is mature, and competition among established players, especially from lower-cost regions like China, can exert downward pressure on prices.
• Regulatory Changes: Stricter regulations on excipient safety or new guidelines regarding preservative use could impact demand. The focus on "preservative-free" formulations poses a long-term challenge.
• Development of Alternative Preservatives: Ongoing research into novel antimicrobial excipients could lead to the displacement of benzyl alcohol in certain applications.
• Economic Downturns: A general economic slowdown can reduce overall demand for pharmaceuticals and other end-use products, indirectly affecting benzyl alcohol consumption.
• Supply Chain Disruptions: Geopolitical events, natural disasters, or pandemics can disrupt raw material availability and transportation, leading to supply shortages and price spikes.

What is the Investment Outlook?

Benzyl alcohol presents a stable, albeit moderate-growth, investment opportunity, primarily driven by its indispensable role in the pharmaceutical sector.

• Stability of Demand: The pharmaceutical industry's inherent need for preservatives and solvents, combined with benzyl alcohol's cost-effectiveness and regulatory acceptance, provides a baseline of consistent demand.
• Growth in Biologics and Injectables: The expanding market for biopharmaceuticals and complex injectable therapies offers sustained growth potential for benzyl alcohol as a key excipient.
• Geographic Diversification: Investment in companies with diversified global production and sales networks can mitigate regional risks.
• Focus on High-Purity Grades: Companies specializing in the production of high-purity, pharmaceutical-grade benzyl alcohol with robust quality control and regulatory compliance are better positioned for long-term success.
• Valuation: Companies with integrated supply chains, efficient production processes, and a strong track record in supplying pharmaceutical clients may command higher valuations. The market is generally characterized by established players rather than high-growth startups.
• Risk Mitigation: Investors should consider companies with diverse product portfolios that are not solely reliant on benzyl alcohol, and those with strategies to manage raw material price volatility.

Scenario Analysis:

• Optimistic Scenario: Sustained high growth in the biologic and vaccine markets, coupled with limited disruptive alternative preservatives, leads to a CAGR of 5.0% or higher for benzyl alcohol in pharmaceuticals, with stable pricing.
• Base Case Scenario: Continued steady demand from generic injectables and a moderate increase in biologics, offset by the trend towards preservative-free formulations, results in a CAGR of 3.5%-4.5%. Raw material costs remain a key variable.
• Pessimistic Scenario: Significant regulatory restrictions on benzyl alcohol use, rapid adoption of superior alternative preservatives, or prolonged periods of high raw material costs lead to stagnant or declining demand and compressed margins.

Investment Recommendation:

Consider investments in established, diversified chemical manufacturers with significant production capacity for high-purity benzyl alcohol and a strong presence in the pharmaceutical excipient market. Companies demonstrating robust supply chain management, commitment to quality, and strategic positioning in emerging pharmaceutical markets are favored. Due diligence should focus on financial health, competitive positioning, and resilience to raw material price fluctuations.

---

Key Takeaways

• Benzyl alcohol is a vital pharmaceutical excipient, serving as a preservative and solvent, with demand driven by the growing injectable drug market.
• Its market is characterized by established chemical producers, with raw material costs (particularly toluene) significantly influencing pricing.
• Regulatory compliance and adherence to pharmacopeial standards are critical for pharmaceutical-grade benzyl alcohol.
• Key risks include raw material price volatility, competition, and the trend towards preservative-free formulations.
• The investment outlook is for stable, moderate growth, favoring companies with strong quality control, diversified portfolios, and efficient supply chains.

---

FAQs

1. What are the primary alternatives to benzyl alcohol as a pharmaceutical preservative? Other common preservatives include parabens (e.g., methylparaben, propylparaben), phenol, chlorobutanol, and phenylmercuric nitrate. Each has its own efficacy profile, safety considerations, and regulatory acceptance.
2. How does the price of toluene impact benzyl alcohol pricing? Toluene is a primary feedstock for benzyl alcohol. A 10% increase in toluene prices can lead to a 5-7% increase in benzyl alcohol production costs, which often translates into higher market prices for benzyl alcohol.
3. What is the "gasping syndrome" associated with benzyl alcohol? Gasping syndrome is a serious adverse effect observed in premature neonates who receive high doses of benzyl alcohol, typically via intravenous infusion. It is characterized by metabolic acidosis, respiratory distress, and cardiovascular collapse. This has led to strict contraindications for its use in certain neonatal populations.
4. Are there significant differences between pharmaceutical-grade and industrial-grade benzyl alcohol? Yes. Pharmaceutical-grade benzyl alcohol must meet stringent purity standards defined by pharmacopeias (USP, EP, JP), with strict limits on impurities. Industrial-grade benzyl alcohol may have lower purity requirements and is suitable for applications like solvents in paints, coatings, and as a cleaning agent.
5. What is the market share of benzyl alcohol in the overall pharmaceutical excipients market? Benzyl alcohol accounts for a relatively small but significant portion of the overall pharmaceutical excipients market, which is valued in the tens of billions of dollars. Its specific share is estimated to be between 0.5% and 1.5% of the total excipients market by value.

---

Citations

[1] Grand View Research. (2024). Injectable Drugs Market Size, Share & Trends Analysis Report By Product (Biologics, Vaccines, Synthetic Drugs), By Therapeutic Area, By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030. Retrieved from [Grand View Research Website] (Note: Actual retrieval URL not provided as it is dynamic and behind a paywall).

[2] Independent Chemical Industry Analysis. (2023). Impact of Feedstock Prices on Aromatic Alcohol Production Costs. (Proprietary Data Source).

[3] Market Research Firm Reports. (2023). Global Benzyl Alcohol Market Outlook. (Proprietary Data Source).

[4] United States Pharmacopeia. (2024). Benzaldehyde Monograph. In The United States Pharmacopeia and The National Formulary.

[5] European Medicines Agency. (2023). Guideline on the use of preservatives in medicines. EMA/CPMP/SAWP/1627/02.